Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762:TWSE), powered by AI.

Current Price
$35.35
Sector
Healthcare
What is the Chunghwa Chemical Synthesis & Biotech Co., Ltd. stock price forecast?

Chunghwa Chemical Synthesis & Biotech Co., Ltd. is currently trading at $35.35. View real-time AI analysis on Alpha Lenz.

What is Chunghwa Chemical Synthesis & Biotech Co., Ltd. insider trading activity?

View the latest insider trading data for Chunghwa Chemical Synthesis & Biotech Co., Ltd. on Alpha Lenz.

What is Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s P/E ratio?

View Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

TWSE · 1762
NT$35.35+0.65(+1.87%)
Ask about Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s ROE is -7.6%. Explore profitability and growth together.

Ask for details

Company Overview

Chunghwa Chemical Synthesis & Biotech Co., Ltd. is a prominent player in the pharmaceutical and biotechnology industry, primarily focused on the development, manufacture, and distribution of high-quality chemical synthesis products and biotech solutions. Its operations span from producing active pharmaceutical ingredients (APIs) to delivering advanced biotech products, supporting both healthcare and research institutions. The company is known for its emphasis on innovation and strict adherence to quality standards, which helps it cater to a wide range of therapeutic areas, including oncology, neurology, and infectious diseases. Based in Taiwan, Chunghwa Chemical Synthesis & Biotech serves a global market, leveraging its state-of-the-art facilities and expertise to contribute significantly to advancements in healthcare and improving patient outcomes. By continually expanding its product portfolio and forging strategic partnerships, the company plays a vital role in addressing the ever-evolving demands of the pharmaceutical and biotechnology landscapes.

SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$804.88MRevenue
0.00Shares Out
0Employees

Margins

-1.10%Gross
-5.91%EBITDA
-39.70%Operating
-31.77%Pre-Tax
-30.30%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-27.56%Rev 3Yr
-12.21%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-5.37%ROA
-7.57%ROE
-5.26%ROIC

Financial Health

NT$216.44MCash & Cash Equivalents
NT$1.01BNet Debt
39.84%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (ticker: 1762) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 35.35 with a P/E ratio of -x and P/B of -x.

ROE is -7.57% and operating margin is -39.70%. Annual revenue is $805M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762) Stock Forecast 2026 $35.35 — Price, Financials & Analyst Targets | Alpha Lenz